Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs GeneDx Holdings Corp — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $333 (market cap $4.10B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: First Trust NASDAQ 100 Technology Index Fund is far larger — about 2× GeneDx Holdings Corp's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ 100 Technology Index Fund for 40 Days and GeneDx Holdings Corp for 19 Days on average.
| QTEC | WGS | |
|---|---|---|
Market Cap | $4.10B | $2.02B |
Volume | 264,303 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $340.28 | $167.51 |
52-Week Low | $207.03 | $34.51 |
Typical Hold Time | 40 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC trades at $335.82, down 1.31% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, offering diversification across software and hardware sectors. Recent analysis highlights software industry undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar funds.
The outlook remains cautiously optimistic given technology sector growth potential, though overbought RSI levels suggest near-term consolidation. Key risks include sector volatility and macroeconomic pressures on tech valuations, while institutional interest supports long-term stability.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
